- Home
- SRRK vs VIST Comparison
SRRK vs VIST Comparison
Compare SRRK & VIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRRK | VIST |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | Mexico |
| Employees | 289 | 584 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRRK | VIST |
|---|---|---|
| Price | $56.97 | $64.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $56.17 | ★ $81.33 |
| AVG Volume (30 Days) | ★ 1.5M | 859.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.93 |
| Revenue Next Year | $534.24 | $20.35 |
| P/E Ratio | ★ N/A | $7.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $33.37 |
| 52 Week High | $58.12 | $81.44 |
Technical Indicators
Market Signals| Indicator | SRRK | VIST |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 41.59 |
| Support Level | $41.38 | $61.88 |
| Resistance Level | N/A | $77.59 |
| Average True Range (ATR) | 2.45 | 2.31 |
| MACD | 0.52 | 0.03 |
| Stochastic Oscillator | 85.32 | 44.28 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
About VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, it operates in Argentina and Mexico. Product-wise, the firm generates the majority of its revenue from crude oil sales, natural gas sales, and LPG sales.